Roxithromycin targets bacterial infections by binding to the bacterial ribosome’s 50S subunit. This prevents protein synthesis, effectively stopping the bacteria from multiplying and causing further damage. This mechanism differs slightly from erythromycin, its close relative, leading to enhanced activity against certain bacteria.
Targeting Specific Bacteria
Roxithromycin exhibits strong activity against a wide range of common bacterial pathogens, including Streptococcus pneumoniae (responsible for pneumonia and other respiratory infections), Haemophilus influenzae (contributing to ear infections and bronchitis), and Mycoplasma pneumoniae (a cause of atypical pneumonia). Its effectiveness extends to certain strains of Staphylococcus aureus and Legionella pneumophila.
Absorption and Excretion
After oral administration, roxithromycin is readily absorbed, leading to therapeutic concentrations in tissues. It has a longer half-life compared to erythromycin, allowing for once-daily dosing and improved patient compliance. The drug is primarily metabolized in the liver and excreted through both urine and feces.
Dosage and Administration
Always follow your doctor’s instructions regarding dosage and treatment duration. Typical dosages vary based on the infection’s severity and the patient’s individual factors. Complete the prescribed course of treatment, even if symptoms improve, to prevent recurrence. Consult your physician or pharmacist for detailed information.
